Free Trial

Orchestra BioMed Q1 2024 Earnings Report

Orchestra BioMed logo
$4.92 +0.12 (+2.50%)
(As of 12/20/2024 05:16 PM ET)

Orchestra BioMed EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.62 million
Expected Revenue
$1.28 million
Beat/Miss
Missed by -$660.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Q1 2024
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Orchestra BioMed Earnings Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat

Upcoming Earnings